Syringaresinol Inhibitor

(-)-Syringaresinol may be a potential chemotherapeutic agent for the treatment,of cancer; it against H/R-induced cardiomyocyte injury and death, the degradation of HIF-1alpha+/- through activation of FOXO3 is a potential therapeutic strategy for ischemia-related diseases.

Syringaresinol protects against hypoxia/reoxygenation-induced cardiomyocytes injury and death by destabilization of HIF-1alpha+/- in a FOXO3-dependent mechanism.Oncotarget. 2015 Jan 1;6(1):43-55.
Syringaresinol protects against hypoxia/reoxygenation-induced cardiomyocytes injury and death by destabilization of HIF-1alpha+/- in a FOXO3-dependent mechanism.Oncotarget. 2015 Jan 1;6(1):43-55.
(-)-Syringaresinol inhibits proliferation of human promyelocytic HL-60 leukemia cells via G1 arrest and apoptosis. Int Immunopharmacol. 2008 Jul;8(7):967-73.

Small volumes of Syringaresinol, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5760959 is an inhibitor targeting Syringaresinol.